Loxo Oncology (Loxo Oncology) Net Margin % : -63.72% (As of Sep. 2018)

View and export this data going back to 2014. Start your Free Trial

What is Loxo Oncology Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Loxo Oncology's Net Income for the three months ended in Sep. 2018 was $-27.1 Mil. Loxo Oncology's Revenue for the three months ended in Sep. 2018 was $42.5 Mil. Therefore, Loxo Oncology's net margin for the quarter that ended in Sep. 2018 was -63.72%.

The historical rank and industry rank for Loxo Oncology's Net Margin % or its related term are showing as below:

LOXO's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -156.83
* Ranked among companies with meaningful Net Margin % only.

Loxo Oncology Net Margin % Historical Data

The historical data trend for Loxo Oncology's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Loxo Oncology Net Margin % Chart

Loxo Oncology Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Net Margin %

-698.95

Loxo Oncology Quarterly Data
	Sep13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
Net Margin %	Get a 7-Day Free Trial															-	-96.85	-9.26	-27.53	-63.72

Competitive Comparison of Loxo Oncology's Net Margin %

For the Biotechnology subindustry, Loxo Oncology's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Loxo Oncology's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Loxo Oncology's Net Margin % distribution charts can be found below:

* The bar in red indicates where Loxo Oncology's Net Margin % falls into.

Loxo Oncology Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Loxo Oncology's Net Margin for the fiscal year that ended in Dec. 2017 is calculated as

Net Margin	=	Net Income (A: Dec. 2017 )	/	Revenue (A: Dec. 2017 )
	=	-148.876	/	21.3
	=	-698.95 %

Loxo Oncology's Net Margin for the quarter that ended in Sep. 2018 is calculated as

Net Margin	=	Net Income (Q: Sep. 2018 )	/	Revenue (Q: Sep. 2018 )
	=	-27.064	/	42.47
	=	-63.72 %

Loxo Oncology (NAS:LOXO) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Loxo Oncology Net Margin % Related Terms

Thank you for viewing the detailed overview of Loxo Oncology's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Loxo Oncology (Loxo Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Loxo Oncology Inc (NAS:LOXO) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.loxooncology.com

Loxo Oncology Inc develops medicines for patients with genetically defined cancers. Its approach is based on the increasing use of genetic testing in cancer clinical medicine and improving chemistry approaches to building inhibitors against single targets in the cancer cell. Its pipeline of products includes Larotrectinib, Loxo etc.

Executives

Jennifer Burstein	officer: Senior VP of Finance	C/O LOXO ONCOLOGY, INC., ONE LANDMARK SQUARE, SUITE 1122, STAMFORD CT 06901
Keith T. Flaherty	director	55 FRUIT STREET, YAWKEY 9E, BOSTON MA 02114
Lori Anne Kunkel	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Joshua H. Bilenker	director, officer: President & CEO	C/O LOXO ONCOLOGY, INC., ONE LANDMARK SQUARE, SUITE 1122, STAMFORD CT 06901
Steve Elms	director, 10 percent owner	888 SEVENTH AVE, 29TH FL, NEW YORK NY 10106
Alan Fuhrman	director	C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Timothy M Mayleben	director	3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
Andrew N Schiff	10 percent owner	PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Dennis J Purcell	10 percent owner	AUXILIUM PHARMACEUTICALS, INC., 160 WEST GERMANTOWN PIKE, NORRISTOWN PA 19401
Aisling Capital Iii Lp	10 percent owner	888 Seventh Avenue, 30th Fl, New York NY 10106
Aisling Capital Partners Iii Lp	10 percent owner	AISLING CAPITAL LLC, 888 SEVENTH AVENUE 30TH FLOOR, NEW YORK NY 10106
Aisling Capital Partners Iii Llc	10 percent owner	AISLING CAPITAL LLC, 888 SEVENTH AVENUE 30TH FLOOR, NEW YORK NY 10106
Orbimed Advisors Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp V Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Samuel D Isaly	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022